← 홈

ADC · 난소암

112개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 112개
ADCBiologicstaleVerastem, Inc.Phase 2

Defactinib (Defactinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3.2%임상시험 30상태 RECRUITING
ADCBiologicstaleJanssen Research & Development,…Phase 2

Erdafitinib (Erdafitinib)

Muscle Invasive Bladder Urothelial Carcinoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 46.9%임상시험 30상태 RECRUITING
ADCBiologicstaleCalithera Biosciences, IncPhase 2

Sapanisertib (Sapanisertib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 18.4%임상시험 30상태 RECRUITING
ADCBiologicstaleAbbViePhase 3

MIRV (Mirvetuximab Soravtansine, Mirvetuximab Soravtansine (MIRV))

Epithelial Ovarian Cancer · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 28상태 RECRUITING
ADCBiologicstaleAbbViePhase 3

Mirvetuximab soravtansine (Mirvetuximab soravtansine)

Endometrial Cancer; Endometrial Adenocarcinoma · Ovarian Cancer

#OvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 27상태 ACTIVE
ADCBiologicstaleAbbViePhase 2

MIRV; IMGN853 (mirvetuximab soravtansine, mirvetuximab soravtansine (MIRV; IMGN853))

Ovarian Cancer; Fallopian Tube · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 100%임상시험 27상태 RECRUITING
ADCBiologicNational Cancer Institute (NCI)vedotin, and venetoclax dem…Phase 2

Larotrectinib (Larotrectinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 94.4%임상시험 25상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 2%임상시험 24상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 2

Dabrafenib Mesylate (Dabrafenib Mesylate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 61%임상시험 24상태 RECRUITING
ADCBiologicstaleBristol-Myers SquibbPhase 1

Verapamil Hydrochloride (Verapamil Hydrochloride)

Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 19상태 ACTIVE
ADCBiologicstaleAstraZenecaPhase 2

AZD5305 (Saruparib, Saruparib (AZD5305))

Ovarian Cancer; Lung Adenocarcinoma · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 18상태 RECRUITING
ADCBiologicstaleBioMed Valley Discoveries, IncPhase 2

Ulixertinib (Ulixertinib)

Metastatic Colorectal Cancer · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 2%임상시험 18상태 RECRUITING
ADCBiologicstaleEli Lilly and CompanyPhase 3

MIRV (MIRV)

Ovarian Neoplasms; Fallopian Tube Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 51.9%임상시험 17상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

AZD5305 (AZD5305)

Ovarian Cancer; Breast Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

Camizestrant (Camizestrant)

Ovarian Cancer; Breast Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 15.7%임상시험 14상태 RECRUITING
ADCBiologicstaleBayerPhase 2

Copanlisib Hydrochloride (Copanlisib Hydrochloride)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 38.5%임상시험 13상태 RECRUITING
ADCBiologicstaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48 + Carboplatin)

Ovarian Cancer; HER2 · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 11상태 RECRUITING
ADCBiologicstaleGenentech, Inc.Phase 2

Taselisib (Taselisib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 50%임상시험 10상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 2

PI3K-beta Inhibitor GSK2636771 (PI3K-beta Inhibitor GSK2636771)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 9%임상시험 8상태 RECRUITING
ADCBiologicGenmabPhase 3

Rina-S (Rina-S)

High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 8상태 RECRUITING

3 / 6 페이지

← 이전다음 →